Next Step for Onyx Pharma: 2011 Is Defining Year

Onyx Pharmaceuticals Inc.’s growing pipeline, including one high-profile compound finishing successful Phase II clinical trials, appears to be finally moving the company beyond its considerable reliance on its flagship cancer drug Nexavar (sorafenib).